BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Full Year 2024 Results Key Financial Results Revenue: US$63.5m (down 83% from ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

Reports Q4 revenue $30.1M, consensus $16.47M. “We are incredibly proud of the significant progress and momentum across our hematology and ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago. These ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th.Analysts expect Beam Therapeutics to ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...